Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
As one might expect, there is an extremely diverse (and conflicting) range of reactions to the USPSTF recommendation that routine PSA testing of uninformed men is not supported by good evidence and should no longer be considered as appropriate “standard” practice unless there has been a prior discussion of the risks and benefits of the [...]
Filed under: Diagnosis, Management, Risk | Tagged: benefit, cost, coverage, PSA, risk, USPSTF | 6 Comments »
As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a Comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) – improves health outcomes for Medicare beneficiaries
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a Comment »
Physicians and researchers on a panel advising the Centers for Medicare & Medicaid Services (CMS) gave Provenge® a favorable vote at a “National Coverage Analysis” hearing yesterday in Washington, DC. You could almost hear the world of prostate cancer survivors, their physicians, Dendreon investors, and other drug development companies breathe a sigh of relief!
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coverage, Medicare, Provenge, sipuleucel-T | 2 Comments »
Yesterday evening, the Centers for Medicare and Medicaid Services (CMS) announced that it was opening a “national coverage analysis to determine whether or not autologous cellular immunotherapy [for prostate cancer with sipuleucel-T/Provenge] is reasonable and necessary.”
Filed under: Management | Tagged: coverage, Medicaid, Medicare, Provenge, sipuleucel-T | 3 Comments »
Reuters has published a summary report on the discussions of a Medicare advisory panel (MedCAC) held yesterday to address the value of different types of radiation therapy in the treatment of early-stage prostate cancer.
Filed under: Management | Tagged: coverage, CyberKnife, Medicare, radiation | Leave a Comment »
Many readers will be interested in the article titled “Debate surrounds new prostate-cancer treatment” that appeared today in the Philadelphia Inquirer on the topic of prostate cancer treatment costs.
Filed under: Management, Treatment | Tagged: coverage, CyberKnife, radiotherapy | 5 Comments »
According to an article originally published in the Gray Sheet last week and in OncologySTAT today, Blue Cross Blue Shield of Michigan has formally asked the Centers for Medicare and Medicaid Services (CMS) to issue a national non-coverage decision for proton therapy in treating prostate cancer.
Filed under: Management, Treatment | Tagged: coverage, proton beam radiation | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site